SERPINB9 is commonly amplified and high expression in cancer cells correlates with poor immune checkpoint blockade response

Immunotherapies, in particular immune checkpoint blockade (ICB), have improved the clinical outcome of cancer patients, although many fail to mount a durable response. Several resistance mechanisms have been identified, but our understanding of the requirements for a robust ICB response is incomplet...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Sofía Ibáñez-Molero, Alex van Vliet, Joanna Pozniak, Karlijn Hummelink, Alexandra M. Terry, Kim Monkhorst, Joyce Sanders, Ingrid Hofland, Ewout Landeloos, Yannick Van Herck, Oliver Bechter, Thomas Kuilman, Weiwei Zhong, Jean-Christophe Marine, Lodewyk Wessels, Daniel S. Peeper
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Taylor & Francis Group 2022-12-01
Edice:	OncoImmunology
Témata:	Cancer immunotherapy SERPINB9 NSCLC melanoma
On-line přístup:	https://www.tandfonline.com/doi/10.1080/2162402X.2022.2139074
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!